TELIX PHARMACEUTICALS LTD (ASX: TLX)

ASX: TLX (TELIXPHARM FPO [TLX])

Kemas kini terakhir: 04 May, 10:46AM

1.33 (4.75%)

Tambah ke senarai pantauan

Harga / Pendapatan (P/E TTM)	209.43
Harga / Pendapatan (P/E Ke hadapan)	60.61
Harga / Jualan (P/S)	5.59
Harga / Buku (P/B)	8.08

Julat 52 Minggu	14.42 (-50%) — 31.97 (9%)
Tarikh Pendapatan	20 Feb 2025

Arah Aliran Pasaran

AISkor Stockmoo

-0.6

Saham Serupa

Stok	Modal Pasaran	DY	P/E (TTM)	P/B
TLX	10 B	-	209.43	8.08
CSL	101 B	1.60%	22.23	3.27
MSB	2 B	-	-	3.92
NEU	2 B	-	17.16	8.40
PYC	834 M	-	-	3.92
IMM	367 M	-	-	2.81

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Sektor	Healthcare
Industri	Biotechnology
Gaya Pelaburan	Mid Growth
% Dimiliki oleh Orang Dalam	20.80%
% Dimiliki oleh Institusi	18.80%

Tiada data dalam julat masa ini.

Portfolio

AI Templat

Peringatan harga anda

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Tiada saham yang memenuhi kriteria anda

Margin Keuntungan	6.37%
Margin Operasi (TTM)	8.46%
EPS Cair (TTM)	0.150
Pertumbuhan Hasil Suku Tahunan (YOY)	48.80%
Pertumbuhan Pendapatan Suku Tahunan (YOY)	3.80%

Jumlah Hutang/Ekuiti (D/E MRQ)	102.33%
Nisbah Semasa (MRQ)	2.78
Aliran Tunai Operasi (OCF TTM)	43.03 M
Aliran Tunai Bebas Leveraj (LFCF TTM)	72.81 M

Pulangan Atas Aset (ROA TTM)	5.32%
Pulangan Atas Ekuiti (ROE TTM)	13.92%